| Study name |
K-ras status |
Treatment |
RR (CR+PR)
(%) |
mPFS
(months) |
mOS
(months) |
|
CRYSTAL |
Wild type
(n=348) |
FOLFIRI+C-mab
FOLFIRI |
59.3 (p=0.003)
43.2 |
9.9 (p<0.017)
8.7 |
24.9
21.0 |
Mutant
(n=192) |
FOLFIRI+C-mab
FOLFIRI |
36.2 (p=0.46)
40.2 |
8.1
7.6 |
17.5
17.7 |
|
OPUS |
Wild type
(n=134) |
FOLFOX+C-mab
FOLFOX |
60.7 (p<0.011)
37 |
7.7 (p<0.016)
7.2 |
N.R.
N.R. |
Mutant
(n=99) |
FOLFOX+C-mab
FOLFOX |
32.7
49 |
8.6 (p<0.02)
5.5 |
N.R.
N.R. |
RR: response rate, CR: complete response, PR: partial response, mPFS: median progression free survival, mOS: median overall survival, N.R.: not reported. C-mab:
cetuximab, FOLFIRI: irinotecan/5-FU/leucovorin, FOLFOX: oxaliplatine/5-FU/leucovorin |
